Imunon Inc

IMNN

Company Profile

  • Business description

    Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

  • Contact

    997 Lenox Drive
    Suite 100
    LawrencevilleNJ08648
    USA

    T: +1 609 896-9100

    E: [email protected]

    https://www.imunon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    20

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,958.0039.30-0.44%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,289.02219.15-0.93%
NASDAQ24,328.38181.38-0.74%
Nikkei 22558,696.54163.89-0.28%
NZX 50 Index14,301.795.17-0.04%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,844.9038.30-0.43%
SSE Composite Index3,576.518.06-0.22%

Market Movers